Last reviewed · How we verify
Brimonidine 0.2% ophthalmic solution
At a glance
| Generic name | Brimonidine 0.2% ophthalmic solution |
|---|---|
| Also known as | ALPHAGAN® |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
- The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA (PHASE4)
- A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome (NA)
- Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) (PHASE3)
- Dry Eye Disease Study With Brimonidine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |